Clinically, neuroblastoma patients are classified into low‐, intermediate‐, and high‐risk groups based on factors including age at diagnosis, disease stage, histopathological characteristics, MYCN amplification, and other genetic markers [3]. The gene discussed is MYCN; the disease is neuroblastoma.